NASDAQ
Citius Pharmaceuticals, Inc. (CTXR)
♥ 295 Thanks from members
Citius Pharmaceuticals (CTXR) exhibits a mixed market sentiment; commercial traction from LYMPHIR through subsidiary Citius Oncology offers foundational growth, yet heavy operating losses, cash burn, and shareholder dilution keep institutional AI scores anchored in neutral-to-hold territory.